01865nas a2200337   4500000000100000008004100001260001300042653002200055653002300077653002000100653003000120653002000150653003500170653002500205653001100230653002300241653002000264653002100284653001200305100002100317700001600338700002200354700001700376700001600393700001400409245008300423300001000506490000600516520099100522022001401513       1973                            d  c1973 Apr10aAntibodies, Viral10aAntibody Formation10aAntigens, Viral10aComplement Fixation Tests10aCytomegalovirus10aFluorescent Antibody Technique10aHerpesvirus 4, Human10aHumans10aImmunity, Cellular10aImmunodiffusion10aImmunoglobulin G10aleprosy1 aPapageorgiou P S1 aSorokin C F1 aKouzoutzakoglou K1 aBonforte R J1 aWorkman P L1 aGlade P R00aHost responses to Epstein-Barr virus and cytomegalovirus infection in leprosy.  a620-40 v73 a<p>A study was undertaken in patients with leprosy to assess the contribution of cell-mediated immunity to the host response to Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infection. Sixteen of 72 patients (22%) with lepromatous leprosy, with impaired cellular immunity, had anti-EBV titers of 1,640 or higher. Only 4 of 49 patients (8%) with tuberculoid leprosy, with intact cell-mediated immunity, attained the level of 1:640. The anti-EBV antibody titers were significantly higher in patients with lepromatous leprosy (P approximately 0.025). No significant differences were found in the level of anti-CMV antibody titers in patients with the two types of leprosy. The presence of high anti-EBV antibody titers in lepromatous leprosy suggests that cell-mediated immunity is a significant factor in host response to EBV infection. Host immune responses should be taken into consideration when assignment of an etiological role to EBV is based upon seroepidemiological data.</p>  a0019-9567